Karl Dykema
Overview
Explore the profile of Karl Dykema including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saulnier Sholler G, Bergendahl G, Lewis E, Kraveka J, Ferguson W, Nagulapally A, et al.
Genome Med
. 2024 Feb;
16(1):28.
PMID: 38347552
Background: Children with relapsed central nervous system (CNS tumors), neuroblastoma, sarcomas, and other rare solid tumors face poor outcomes. This prospective clinical trial examined the feasibility of combining genomic and...
2.
Eslin D, Zage P, Bergendahl G, Lewis E, Roberts W, Kraveka J, et al.
Int J Cancer
. 2023 May;
153(5):1026-1034.
PMID: 37246577
Children with relapsed/refractory (R/R) neuroblastoma (NB) and medulloblastoma (MB) have poor outcomes. We evaluated the efficacy of nifurtimox (Nfx) in a clinical trial for children with R/R NB and MB....
3.
Luchtefeld M, Jrebi N, Hostetter G, Osterholzer K, Dykema K, Khoo S
J Surg Res
. 2022 Jul;
279:464-473.
PMID: 35842971
Introduction: Collagen degradation can lead to early postoperative weakness in colorectal anastomosis. Matrix metalloproteinase inhibitors (MMPIs) are shown to decrease collagen breakdown and enhance healing in anastomosis in animal models....
4.
Byron S, Hendricks W, Nagulapally A, Kraveka J, Ferguson W, Brown V, et al.
Cancer Res
. 2021 Oct;
81(23):5818-5832.
PMID: 34610968
Children with treatment-refractory or relapsed (R/R) tumors face poor prognoses. As the genomic underpinnings driving R/R disease are not well defined, we describe here the genomic and transcriptomic landscapes of...
5.
Gao C, Su Y, Koeman J, Haak E, Dykema K, Essenberg C, et al.
Proc Natl Acad Sci U S A
. 2016 Dec;
113(51):14793-14798.
PMID: 27930335
Chromosome instability (CIN) is the most striking feature of human cancers. However, how CIN drives tumor progression to metastasis remains elusive. Here we studied the role of chromosome content changes...
6.
Chen J, Huang D, Rubera I, Futami K, Wang P, Zickert P, et al.
Kidney Int
. 2015 Jun;
88(5):1057-69.
PMID: 26083655
The study of kidney cancer pathogenesis and its treatment has been limited by the scarcity of genetically defined animal models. The FLCN gene that codes for the protein folliculin, mutated...
7.
Foley J, Scholten 2nd D, Monks N, Cherba D, Monsma D, Davidson P, et al.
J Transl Med
. 2015 Apr;
13:110.
PMID: 25889105
Background: Osteosarcoma (OS) is the most common type of solid bone cancer, with latent metastasis being a typical mode of disease progression and a major contributor to poor prognosis. For...
8.
Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, et al.
Genes Cancer
. 2013 Oct;
4(7-8):247-60.
PMID: 24167653
Hepatitis B virus (HBV) is a well-known cause of hepatocellular carcinoma (HCC), but the regulators effectively driving virus production and HCC progression remain unclear. By using genetically engineered mouse models,...
9.
Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kahnoski R, et al.
Cancer Res
. 2013 Feb;
73(7):2044-51.
PMID: 23365135
Sustained activation of the stress-regulated transcription factor NRF2 (NFE2L2) is a prominent feature of many types of cancer, implying that mutations driving NRF2 may be important to tumor progression. In...
10.
Resau J, Ho N, Dykema K, Faber M, Busik J, Nickolov R, et al.
Int J Mol Sci
. 2012 Sep;
13(8):9599-9608.
PMID: 22949818
Screening newborns for treatable serious conditions is mandated in all US states and many other countries. After screening, Guthrie cards with residual blood (whole spots or portions of spots) are...